

Paediatric Strategy Forum Medicinal product development for mature B cell malignancies in children

Date: 13 – 14 November 2017

Venue: EMA, 30 Churchill Pl, Canary Wharf, London, UK

13 November 2017

- 10.00 - 10.20 Introduction - Gilles Vassal, Andy Pearson, Koen Norga, Giovanni Lesa, Franca Ligas (ACCELERATE and European Medicines Agency)
- 10.20 - 10.50 Spectrum of mature B cell malignancies in children compared to adults - Tom Gross (NCI, USA)
- 10.50 - 11.20 Therapy of adult B cell malignancies - Robert Markus (London)
- 11.20 – 11.40 Molecular difference between pediatric and adults mature B Cell malignancies – Wolfram Klapper (Christian-Albrechts-University Kiel, Germany)
- 11.40 - 13.30 Therapeutic needs of B cell malignancies in children
- 11.40 - 12.10 Inter-B-NHL Ritux 2010 study perspective - Veronique Minard-Colin (Gustave Roussy, France)
 - 12.10 - 12.40 BFM Non-Hodgkin's Lymphoma study - Birgit Burkhardt (University of Munster, Germany)
 - 12.40 - 13.10 North American perspective - Tom Gross (NCI, USA)
 - 13.10 - 13.30 Discussion
- 13.30 - 14.30 *Lunch*
- 14.30 - 15.00 Relapse and refractory disease - Amos Burke (Addenbrooke's, Cambridge, UK)
- 15.00 - 15.30 Therapeutic targets in pediatric non-Hodgkin lymphomas - Rodney Miles (University of Utah, Salt Lake City, USA)
- 15.30 - 15.50 Data in relevant paediatric pre-clinical models - Simon Bomken (University of Newcastle upon Tyne, UK)
- 15.50 - 16.15 CART-Cell - Jochen Büchner (University Hospital Rikshospitalet, Oslo, Norway)
- 16.15 - 16.45 *Coffee*
- 16.45 - 17.00 Review of Paediatric Investigation Plans of medicinal products in mature B cell malignancies in childhood - Lynley Marshall (Royal Marsden Hospital and Institute of Cancer Research, UK)
- 17.00 - 18.00 Review of products by the pharmaceutical industries
- 17.00 - 18.00 Antibody Drug Conjugate
 - CD79 - Polatuzumab vedotin - Roche
 - CD37 - Debio 1562 - Debiopharm International SADiscussion of the role of Antibody Drug Conjugates
 - 17.30 - 18.00 CART Cell
 - CD19 - CTL019 - Novartis
 - CD19 - KTE-C19 - Kite pharmaDiscussion of the role of CAR T Cells
- 19.30 *Networking dinner*

14 November 2017

08.30 - 12.30 Review of products by the pharmaceutical industries

08.30 - 09.30 Monoclonal antibody

- CD20 - Obinutuzumab - Roche
- CD20 - Ofatumumab - Novartis
- LAG-3 - BMS-986016 - BMS

Discussion of the role of monoclonal antibodies

09.30 - 10.00 -T-cell Engager

- CD3-CD19 - Blinitumomab - Amgen
- CD20 - CD3 TCB - RG6026 and CD3 TBD - RG7828 - Roche

Discussion of the role of T-cell Engagers

10.00 - 10.20 - Checkpoint inhibitors

- Pembrolizumab- Merck

Discussion of the role of checkpoint inhibitors

10.20- 10.50 - BCL inhibitors

- Venetoclax - AbbVie

Discussion of the role of BCL inhibitors

10.50 - 11.30 *Coffee break*

11.00 – 12.10 - Cell Signalling Inhibitors

- BTK - Ibrutinib - Jansen
- BTK - Acalabrutinib (ACP-196) - AZD
- ATR - BAY1895344 - Bayer
- BET - BMS986158 - BMS
- PI3-K - Idelalisib - Gilead

Discussion of the role of Cell Signalling Inhibitors

12.10 – 12.30 Targeted thorium conjugate D22-TTC - Bayer

Discussion

12.30 – 13.30 *Lunch*

13.30 – 14.20 IMiDs, Targeted thorium conjugate and Cytotoxic

- IMiDs and CELMoDs : cc-122 and cc-220 - Celgene
- Cytotoxic - Pixantrone - Servier

Discussion

14.20 - 17.00 Overall Perspective

17.00 *Close of meeting*